BT For Life Sciences Launches Schrodinger Into The Cloud
Cloud services to empower researchers in design of compounds and materials
IRVING, Texas, May 3, 2013
IRVING, Texas, May 3, 2013 /PRNewswire/ -- BT and Schrodinger, Inc. today
announced that the two companies are now working together to accelerate the
process of drug discovery and development using the BT for Life Sciences cloud
platform and Schrodinger's powerful scientific software applications.
As part of the joint initiative, Schrodinger becomes a Strategic Member of the
BT for Life Sciences partner ecosystem, helping provide research solutions to
scientists on a global basis. Schrodinger's software tools will be integrated
into BT for Life Sciences as part of BT's R&D Workbench environment. Built on
the BT Cloud Compute platform and unveiled at the 10^th Annual BioIT World
meeting last year, BT for Life Sciences is the first cloud service designed to
enable collaboration within the life sciences industry for increased
productivity in discovery, research and development.
One of Schrodinger's key applications, hosted Seurat, will soon be available
on the BT Cloud Compute Platform. This application contains tools that help
researchers in the discovery and optimization of drug research and provides a
means for sharing real-time analysis across the organization.Using the BT
platform, Schrodinger can easily integrate data and scientific business
processes, enhancing the early discovery process so that ultimately better
compounds can be brought to the clinic faster.
Because BT for Life Sciences was developed as a secure and segregated platform
for scientists, it will enable Schrodinger to work with major pharmaceutical
companies and other biotech organizations that need faster and more innovative
approaches to drug discovery and development. In the past, researchers would
typically provide the IT department with the requirements for each in silico
experiment, which could mean a delay in research and discovery as the
equipment was purchased and the platform built. Using BT's cloud services for
Life Sciences, Schrodinger can now offer their applications quickly and easily
with a click-to-launch approach that uses secure, compliant, and scalable
cloud computing, storage and databanks, in order to process demanding
Dr. Ramy Farid, Schrodinger's president, said: "Integrating Schrodinger's
scientific breakthroughs with BT's cloud services takes us one step closer in
our mission to empower researchers to improve human health and quality of life
through advanced computational techniques. We believe that providing our
applications in BT's cloud environment could transform the way chemists
discover and design compounds and drugs."
Bas Burger, president of Pharmaceutical & Chemical for BT Global Services,
said: "Drawing on BT's years of experience and expertise in the pharmaceutical
industry, our cloud-based service can help accelerate the process of R&D for
companies like Schrodinger. Our goal is to provide the best solutions to our
global pharmaceutical customers that will enable them to meet their mission."
For further information
All news releases can be accessed at our web sites:
http://www.globalservices.bt.com/us/en/news and http://www.btplc.com/news
BT is one of the world's leading providers of communications services and
solutions, serving customers in more than 170 countries. Its principal
activities include the provision of networked IT services globally; local,
national and international telecommunications services to its customers for
use at home, at work and on the move; broadband and internet products and
services and converged fixed/mobile products and services. BT consists
principally of four lines of business: BT Global Services, BT Retail, BT
Wholesale and Openreach.
In the year ended 31 March 2012, BT Group's revenue was £18,897m with profit
before taxation of £2,445m.
British Telecommunications plc (BT) is a wholly-owned subsidiary of BT Group
plc and encompasses virtually all businesses and assets of the BT Group. BT
Group plc is listed on stock exchanges in London and New York.
For more information, visit www.btplc.com
Founded in 1990, Schrodinger is a scientific leader in chemical simulation for
pharmaceutical and biotechnology research. Schrodinger's software is used by
nearly every major pharmaceutical firm worldwide as well as thousands of
smaller firms and academic and government research laboratories. In recent
years, Schrodinger has entered into a number of collaborations with
pharmaceutical and biotech companies in which Schrodinger's technology and
expertise have had a significant impact on early-stage drug discovery
Schrodinger makes significant investments in R&D, which has led to major
advances in the field of computational chemistry; it has achieved
breakthroughs in quantum chemistry, molecular modeling, force fields,
molecular dynamics, protein structure determination, scoring, and virtual
screening. The company's full product offerings range from general molecular
modeling programs to a comprehensive suite of drug design software. Besides
the company's industry-leading drug discovery solutions, Schrodinger is
actively developing state-of-the art simulation tools for materials research
as well as enterprise software that can be deployed throughout an entire
research organization. Schrodinger's methods development and applications
papers have thousands of citations and are often among the most-cited
scientific publications. Schrodinger's science is continually validated
internally and by its users worldwide. Founded in 1990, Schrodinger has
operations in the United States as well as in Europe, India, and Japan.
For more information, please visit www.schrodinger.com.
Contact: Kris Kozamchak, Head of PR and Corporate Relations U.S., at + 1 972
310 9055 or email@example.com
Press spacebar to pause and continue. Press esc to stop.